CClinicalTrials.gg
Status unknownNCT03787550Updated Feb 17, 2020

PK/PD of the Sedatives, Analgesics and Antibiotics in Patients Receiving ECMO

An observational study in Drug Effect, sponsored by Guangdong Provincial People's Hospital. Status unknown at 3 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-02-17.

Sponsored by Guangdong Provincial People's Hospital · Observational

The sponsor has not verified this record recently (last verified May 2019), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
36
Ages
18 Years to 85 Years
Sex
All
01

Study summary

It is a multi-center, open-label, observational study aimed to understand the pharmacokinetics and pharmacodynamics of the commonly used sedative, analgesic and antibiotic drugs in adult patients supported with extracorporeal membrane oxygenation (ECMO), by measuring the plasma concentrations and the clinical effect of dexmedetomidine, midazolam, butorphanol, remifentanil, sufentanil, propofol, linezolid, tigecycline, teicoplanin, caspofungin, voriconazole and meropenem.

02

Conditions studied

  • Drug Effect

Keywords

  • ECMO
  • Sedatives
  • Analgesics
  • Antibiotics
03

In context

Lead sponsor

Guangdong Provincial People's Hospital is the lead sponsor of 231 studies on the registry; 101 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patients undergoing ECMO will be invited to participate. At least 2-12 subjects will be enrolled to build a pharmacokineic model for each drug, and 1-4 subjects for external validation for each drug. The investigators plan to study the sedatives, analgesics and antibiotics with the initial sample size at 36 in total.

Inclusion criteria

  • Patient given the sedatives, analgesics and antibiotics of interest during ECMO.
  • Age from 18 to 85 years old.
  • Multiple blood sampling is acceptable.

Exclusion criteria

Exclusion Criteria:

  • Patients who are allergic to the investigated drugs.
  • Patients who are pregnant.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
36 participants (estimated)
Patient registry
No

Groups and cohorts

  • Model building group

    The data from the patients in the model building group will be used to build the population PK/PD model. Two to six blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.

    Drug: The Sedatives, analgesics and antibiotics

  • Model validation group

    The data from the patients in the model building group will be used to build the population PK/PD model. Two to three blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.

    Drug: The Sedatives, analgesics and antibiotics

Interventions

  • DrugThe Sedatives, analgesics and antibiotics

    The sedatives (dexmedetomidine, midazolam, propofol), analgesics (butorphanol, remifentanil, sufentanil), and six antibiotics (linezolid, voriconazole, tigecycline, teicoplanin, caspofungin and meropenem) will be used according to the clinical need.

06

What researchers measure

Primary outcomes

  1. Minimum Plasma Concentration [Cmin]

    The minimum plasma concentration (the trough concentration), usually collected before the next dose.

    Time frame: Up to 24 hours.

  2. Area Under the Curve [AUC]

    The area under the curve during the dose interval. It also can be calculated by the dose and the clearance of the drug.

    Time frame: Up to 24 hours.

  3. Maximum Plasma Concentration [Cmax]

    The maximum plasma concentration, usually at the end of the infusion during an dose interval.

    Time frame: Up to 24 hours.

Secondary outcomes

  1. ICU mortality

    The intensive care unit (ICU) mortality is calculated as the number of deaths of the enrolled patients admitted to the ICU, divided by the number of the enrolled patient discharges from the ICU (including deaths and transfers), and often presented as percentage.

    Time frame: Up to 60 days.

  2. Hospital mortality

    The hospital mortality is calculated as the number of deaths of the enrolled patients divided by the number of the total enrolled patient, and often presented as percentage.

    Time frame: Up to 60 days.

  3. Mechanical ventilation duration

    Mechanical ventilation duration is the length of days the patients on the mechanical ventilation.

    Time frame: Up to 60 days.

  4. ICU length of stay (LOS)

    ICU length of stay (LOS) is the length of days the patients in the ICU.

    Time frame: Up to 60 days.

07

Study locations

3 of 3 sites recruiting
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
    Recruiting
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong, China
    Recruiting
  • Nanfang Hospital
    Guangzhou, Guangdong, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03787550
Lead sponsor
Guangdong Provincial People's Hospital
Responsible party
Sponsor
First posted
Dec 26, 2018
Start date
Feb 7, 2020 (estimated)
Primary completion
Dec 31, 2021 (estimated)
Completion
Mar 31, 2022 (estimated)
Last update
Feb 17, 2020

Study contacts

Chunbo Chen, Ph. D.
Contact
gghccm@163.com
+86-20-83827812 ext. 51157
Xipei Wang, Ph. D.
Contact
xipei_wang@163.com
+86-20-83827812 ext. 51157
Chunbo Chen, Ph. D.
study chair · Guandong General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion